Historical performance in the Drug Discovery category.
Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Novartis | Myricx Bio | Acquisition | $1.5B | Novartis Bets $1.5 Billion on Myricx ADC Payload Platform |
| Tempus AI, Inc. | Paige | Acquisition | $81.3M | Tempus AI, Inc. acquires Paige in $81.3M predominantly in tempus common stock deal |
| IQVIA Holdings Inc. | Charles River Laboratories | Acquisition | Undisclosed | IQVIA Holdings Inc. to acquire Charles River Laboratories |
| IonQ, Inc. | Oxford Ionics Limited | Acquisition | Undisclosed | IonQ, Inc. to acquire Oxford Ionics Limited |
| AstraZeneca | Modella AI | Acquisition | Undisclosed | AstraZeneca acquires Modella AI |
Page 1 of latest articles and deal coverage.
The deal gives Novartis a differentiated antibody drug conjugate engine as large pharma races to secure better-tolerated oncology assets before clinical validation drives prices higher.